$APVO 9.72 USD +3.97 (69.04%)

$APVO will receive royalty payments from $PFE Pfizer related to sales of a rituximab biosimilar product, RUXIENCE®, which was approved by FDA in July 2019 and launched by $PFE in the United States and Japan in early 2020.